Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose, dose-escalation, open-label safety, tolerability and pharmacokinetics study of rhTPO (Tebiao) in chemotherapy-induced thrombocytopenia
CTR20254893Phase 2Active
- Sponsor
- 3SBio
- Start
- Dec 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia (CIT), Acute Radiation Syndrome (ARS), sponsored by 3SBio. Started Dec 2025; status: active.
02
Drugs
recombinant human thrombopoietin
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)Acute Radiation Syndrome (ARS)
Beyond the preview
Go deeper on CTR20254893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254893.